# US 2026/0097020 A1 · Therapeutic use of aromatase inhibitors and poly (adp-ribose) polymerase (parp) inhibitors for the treatment of malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097020 A1
- Document ID: US20260097020A1
- Status: Published application
- Kind: A1
- Application number: 19/345,169
- Filed: 2025-09-30
- Published: 2026-04-09
- Earliest claimed: 2024-09-30
- Assignees: University of Cincinnati
- Applicants: University of Cincinnati
- Inventors: Pankaj B. Desai; Aniruddha S. Karve; Bhavesh B. Gabani; Sidharth N. Gadgil; Gary A. Gudelsky
- Web page: https://patentgrep.com/patent/US20260097020A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating gliomas, such as glioblastoma, including administering an aromatase inhibitor, such as letrozole, to a subject suffering from a glioma. The method may further include administering the aromatase inhibitor in combination with a poly-ADP ribose polymerase inhibitor, such as olaparib, pamiparib, veliparib or niraparib.

## Claims

### Claim 1

A method comprising:
administering an aromatase inhibitor to a subject;
wherein the subject suffers from a glioma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aromatase inhibitor is letrozole.

### Claim 3 (depends on 1)

The method of claim 1 wherein the glioma is a malignant glioma.

### Claim 4 (depends on 3)

The method of claim 3, wherein the malignant glioma is glioblastoma.

### Claim 5 (depends on 1)

The method of claim 1, where the subject has been diagnosed with a glioma.

### Claim 6 (depends on 5)

The method of claim 5, wherein the glioma is glioblastoma.

### Claim 7 (depends on 2)

The method of claim 2, wherein the subject is also administered temozolomide.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering a poly-ADP ribose polymerase inhibitor in combination with the aromatase inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the poly-ADP ribose polymerase inhibitor is selected from the group consisting of olaparib, pamiparib, veliparib and niraparib.

### Claim 10 (depends on 2)

The method of claim 2, further comprising administering a poly-ADP ribose polymerase inhibitor in combination with letrozole.

### Claim 11 (depends on 10)

The method of claim 10, wherein the poly-ADP ribose polymerase inhibitor is selected from the group consisting of olaparib, pamiparib, veliparib and niraparib.
